Anti-HER2/Neu passive-aggressive immunotherapy

Eric D. Mortenson, Yang Xin Fu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4+ T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.

Original languageEnglish (US)
Article numbere27296
JournalOncoImmunology
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Passive Immunization
T-Lymphocytes
CD40 Ligand
Tumor Microenvironment
Adaptive Immunity
Oncogenes
Leukemia
Therapeutics

Keywords

  • Adaptive immunity
  • Antibody
  • CD4
  • CD40
  • CD40L
  • CD8
  • HER2
  • Herceptin
  • Immunotherapy
  • Neu

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Anti-HER2/Neu passive-aggressive immunotherapy. / Mortenson, Eric D.; Fu, Yang Xin.

In: OncoImmunology, Vol. 3, No. 1, e27296, 01.01.2014.

Research output: Contribution to journalArticle

Mortenson, Eric D. ; Fu, Yang Xin. / Anti-HER2/Neu passive-aggressive immunotherapy. In: OncoImmunology. 2014 ; Vol. 3, No. 1.
@article{0cafb93896174fdebb6d61def40bf8ff,
title = "Anti-HER2/Neu passive-aggressive immunotherapy",
abstract = "Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4+ T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.",
keywords = "Adaptive immunity, Antibody, CD4, CD40, CD40L, CD8, HER2, Herceptin, Immunotherapy, Neu",
author = "Mortenson, {Eric D.} and Fu, {Yang Xin}",
year = "2014",
month = "1",
day = "1",
doi = "10.4161/onci.27296",
language = "English (US)",
volume = "3",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Anti-HER2/Neu passive-aggressive immunotherapy

AU - Mortenson, Eric D.

AU - Fu, Yang Xin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4+ T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.

AB - Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4+ T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.

KW - Adaptive immunity

KW - Antibody

KW - CD4

KW - CD40

KW - CD40L

KW - CD8

KW - HER2

KW - Herceptin

KW - Immunotherapy

KW - Neu

UR - http://www.scopus.com/inward/record.url?scp=84899047501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899047501&partnerID=8YFLogxK

U2 - 10.4161/onci.27296

DO - 10.4161/onci.27296

M3 - Article

VL - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 1

M1 - e27296

ER -